Date: 2017-12-12
Type of information: Nomination
Compound: chief executive officer
Company: Eyevensys (France)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 12, 2017, Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, announced the appointment of Dr. Patricia Zilliox as CEO. Dr. Zilliox joined the Eyevensys board in May 2016. She has more than 25 years of global clinical development expertise and previously served as Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia. From late 2008 until May 2011, Dr. Zilliox was head of clinical development at Alcon Laboratories, managing clinical development programs in areas of eye diseases such as glaucoma, allergy, dry eye, infectious diseases of the eye, and retinal diseases such as dry- and wet-AMD. Dr. Zilliox previously worked for Alcon in Paris, France, where she was responsible for the execution of Alcon’s European ophthalmology clinical trials.
- Dr. Zilliox will lead Eyevensys' efforts to further the clinical development of EYS606. Eyevensys’ lead product EYS606, consists of Eyevensys’ proprietary electro-transfection injection system (ETIS) in combination with a plasmid encoding for the production of anti-TNF?, a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in non-infectious uveitis (NIU). EYS606 is currently in phase I/II clinical trial and has been granted an orphan drug designation by the European Medicines Agency (EMA) for the treatment of NIU.
Financial terms:
Latest news:
Is general: Yes
